Tiziana Life Sciences reported positive Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The study showed statistically significant reduction in microglial activation and clinically meaningful fatigue improvements after 12 weeks, consistent with longer-term benefits observed in an expanded access program. Foralumab demonstrated a favorable safety profile with no serious adverse events or anti-drug antibodies detected. These findings highlight foralumab's potential as a novel treatment for na-SPMS, a condition with no FDA-approved therapies, and Tiziana plans further analysis and regulatory discussions to advance development.
Tiziana Life Sciences' positive Phase 2a INFORM-MS trial results for intranasal foralumab provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 00:31 WIB: out of 150 priced US health-sector stocks, 124 rose and 24 fell. Notable movers include HRTX at USD 0.40 (+40.56%), ABEO at USD 2.67 (-36.09%), and IONS at USD 29.09 (-26.22%).
Security National Financial Corporation reported a 38.6% drop in after-tax earnings for Q3 2026, falling to $6.17 million due to challenging mortgage market conditions and increased interest rates. The mortgage segment faced a $2.65 million loss driv...
JIADE Ltd announced a registered direct offering of 6.67 million Class A shares at $0.18 each, raising approximately $1.2 million before fees. The funds will support its comprehensive education services for adult institutions in China, including soft...
Bureau Veritas disclosed its share and voting rights count as of October 31, 2026, reporting 453,899,720 shares outstanding. The company has a theoretical total of 579,429,535 voting rights, with 567,882,134 exercisable voting rights. This update ref...
Quadient S.A. has disclosed its monthly update on the total number of ordinary shares and voting rights as of October 30, 2026. The company reports 34,468,912 total shares and theoretical voting rights, with 34,091,172 net voting rights. This disclos...
Quadient S.A. disclosed its monthly update on shares and voting rights as of October 30, 2026. The company has a total of 34,468,912 ordinary shares and a net total of 34,091,172 voting rights. This information is relevant for shareholders and invest...
